Vanguards of Health Care by Bloomberg Intelligence
Inside Exact Science’s Next Big Bet - One Blood Draw, More than 50 Cancers
18 Sep 2025
“Our vision as a company is to help eradicate cancer with tests that prevent it, detect it earlier and guide treatment,” says Kevin Conroy, CEO of Exact Sciences. He joins Bloomberg Intelligence analyst Jonathan Palmer on the Vanguards of Health Care podcast to trace Exact’s journey into a cancer-diagnostics leader. From Cologuard’s initial rise to its recently launched Cologuard Plus test, the debut of Cancerguard and expansion into minimal-residual disease (MRD) testing, Conroy shares how science, technology and culture underpin the company’s next decade.See omnystudio.com/listener for privacy information.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Vanguards of Health Care by Bloomberg Intelligence
Transcribed and ready to explore now
Aegis Ventures’ Blueprint for Building AI-Native Companies
04 Dec 2025
Vanguards of Health Care by Bloomberg Intelligence
Beta Bionics Does the Work to Reduce Insulin Pump Burden
20 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Fosun Pharma’s Drive Beyond China
17 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
ARS Pharma’s Clinical Differentiation
13 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Biolinq Introduces New Silicon Tech Opens Next Chapter of Glucose and Analyte Detection
06 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates
27 Oct 2025
Vanguards of Health Care by Bloomberg Intelligence